Seattle Children's-Authored Abstracts | American Society of Hematology 2024 Annual Meeting
Published
Scientists and physician-researchers from Seattle Children’s Research Institute contributed to 16 scientific abstracts being presented at the American Society of Hematology 2024 Annual Meeting:
Myron Evans II, PhD
Shan Lin, PhD
Mignon Loh, MD
- Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
- Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)
- Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma
- Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
- TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
- EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin
- Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL
- Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
- Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity
- Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group
- Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131
Shannon Oda, PhD
- Developing Novel Cell Therapy Strategies to Convert Macrophage Programming and Induce Synergistic, Multicellular Immunity Against AML
- Engineering Synergistic Adoptive Cell Therapies for Enhanced Treatment of Acute Myeloid Leukemia
Jim Olson, MD, PhD
Rachel Rau, MD
- Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731
- Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children’s Oncology Group (COG) Protocols
- TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL
- Immunoglobulin Sequencing Biologically Distinguishes B-Lymphoblastic Lymphoma from Acute Lymphoblastic Leukemia and Reveals a Spectrum of Disease Dissemination across Clinical Stages
Related Categories
Related Articles
Publication Q&A: A Comprehensive Assessment of Associations Between Prenatal Phthalate Exposure and the Placental Transcriptomic Landscape
Published
New research from Drs. Alison Paquette, Sheela Sathyanarayana and Drew Day shows relationships between exposure to certain chemicals called phthalates during pregnancy and the placenta, which may impact fetal development and infant health.
Publication Q&A: ODELAM Rapid Sequence-Independent Detection of Drug Resistance in Isolates of Mycobacterium Tuberculosis
Published
Thurston Herricks shares insights from a recent publication in eLife with contributing authors from the Aitchison Lab at the Center for Global Infectious Disease Research (CGIDR).
Publication Q&A: Crippling Life Support for SARS-CoV-2 and Other Viruses Through Synthetic Lethality
Published
John Aitchison shares insights from a recent publication in the Journal of Cell Biology, with contributing authors from the Center for Global Infectious Disease Research (CGIDR).